Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Sangamo Therapeutics (NASDAQ:SGMO) has received mixed ratings from 4 analysts in the last three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is $2.25, with a high of $3.00 and a low of $1.00, marking a 59.09% decrease from the previous average. Analysts from HC Wainwright & Co. and RBC Capital have lowered their price targets, while Wells Fargo announced an Equal-Weight rating. Sangamo's financials show a significant revenue decline of -64.48% and a net margin of -1108.35%, with an ROE of -56.52% and an ROA of -38.24%, indicating financial challenges.
January 19, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics has mixed analyst ratings and a significant decrease in the average price target, indicating potential investor caution and a bearish outlook in the short term.
The decrease in the average price target suggests that analysts are less optimistic about Sangamo's future performance. Combined with the reported financial challenges such as a significant revenue decline and low profitability metrics, this could lead to a negative short-term impact on SGMO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100